Vaxil Bio Ltd.
VXLLF
$0.02
-$0.13-85.27%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 34.48% | 32.55% | 102.68% | 162.33% | 40.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.39% | 17.68% | 30.53% | 55.89% | -12.63% |
| Operating Income | -31.39% | -17.68% | -30.53% | -55.89% | 12.63% |
| Income Before Tax | 422.29% | 469.03% | 53.95% | 34.83% | 23.98% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 422.29% | 469.03% | 53.95% | 34.83% | 23.98% |
| Earnings from Discontinued Operations | 121.45% | 121.45% | 21.92% | -309.80% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 355.43% | 388.34% | 49.16% | 13.15% | 2.23% |
| EBIT | -31.39% | -17.68% | -30.53% | -55.89% | 12.63% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 336.42% | 350.00% | 49.28% | 13.27% | 2.17% |
| Normalized Basic EPS | 33.20% | 33.77% | 51.70% | 34.88% | 24.21% |
| EPS Diluted | 336.42% | 350.00% | 49.28% | 13.27% | 2.17% |
| Normalized Diluted EPS | 33.20% | 33.77% | 51.70% | 34.88% | 24.21% |
| Average Basic Shares Outstanding | 14.84% | 3.48% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 14.84% | 3.48% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |